Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permittedXx_NEWLINE_xXEvidence of bleeding diathesis or clinically significant coagulopathyXx_NEWLINE_xXPatients with uncontrolled coagulopathy or bleeding disorder are not eligibleXx_NEWLINE_xXKnown bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy. Therapeutic anticoagulation is permitted, but patients must be on a stable dose.Xx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXParticipants with active bleeding disorder/coagulopathyXx_NEWLINE_xXHistory of coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or clinically significant coagulopathy.Xx_NEWLINE_xXPatients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXBleeding disorder/coagulopathyXx_NEWLINE_xXUncontrolled coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathyXx_NEWLINE_xXNo coagulopathy or bleeding diathesisXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation).Xx_NEWLINE_xXEvidence of a bleeding diathesis.Xx_NEWLINE_xXUncontrolled coagulopathy or bleeding disorderXx_NEWLINE_xXKnown coagulopathy or bleeding diathesis; those on therapeutic anticoagulation or anti-platelet agent are permitted only after discussing with the study PIXx_NEWLINE_xXClinical evidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatients with uncontrolled coagulopathy or bleeding disorderXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past yearXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy within 3 months (eg, von Willebrand’s disease or hemophilia.Xx_NEWLINE_xXUncontrolled coagulopathyXx_NEWLINE_xX(Bevacizumab-related exclusion) Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXActive coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXInherited bleeding diathesis or coagulopathy with the risk of bleedingXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXPatients with uncontrolled coagulopathy or bleeding disorderXx_NEWLINE_xXEvidence or history of bleeding diathesisXx_NEWLINE_xXPatients with evidence of bleeding diathesis are not eligibleXx_NEWLINE_xXuncorrectable coagulopathyXx_NEWLINE_xXActive coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation); any history of significant bleeding or thrombosis should be discussed with the study principal investigators (PIs)Xx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Evidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory of or genetic predisposition to a bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesisXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permittedXx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permittedXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anti-coagulation for prior thromboembolic events is permittedXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatients who have clinical history of coagulopathy, bleeding diathesis or thrombosis within the past yearXx_NEWLINE_xXEvidence of clinically significant bleeding diathesis or underlying coagulopathy, non-healing woundXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXThe subject has inherited bleeding diathesis or coagulopathy with the risk of bleedingXx_NEWLINE_xXEvidence of bleeding diathesis, coagulopathy as documented by an elevated PT, PTT or bleeding timeXx_NEWLINE_xXClinical evidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleedingXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy (including clinically significant hemoptysis)Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of active bleeding diathesis or coagulopathy\r\n* For the NSCLC expanded cohort only: history of “blood tinged” sputum allowedXx_NEWLINE_xXNo clinical evidence of hepatic failure (e.g. coagulopathy, ascites)Xx_NEWLINE_xXPatients with uncontrolled coagulopathy or bleeding disorderXx_NEWLINE_xXHaemorrhagic diathesis (i.e. haemophilia)Xx_NEWLINE_xXHistory of abnormal bleeding and coagulopathyXx_NEWLINE_xXBleeding or evidence or history of clinically significant bleeding diathesis or coagulopathy within the last 3 monthsXx_NEWLINE_xXClinically significant bleeding diathesis or coagulopathyXx_NEWLINE_xXUse of full dose, therapeutic anti-coagulation or patients with uncontrolled coagulopathy or bleeding disorderXx_NEWLINE_xXUncontrolled coagulopathyXx_NEWLINE_xXHistory or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleedingXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatients with a known coagulopathy or bleeding diathesis or require the use of systemic anticoagulant medication are not eligibleXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesisXx_NEWLINE_xXClinically significant bleeding diathesis or coagulopathy, including known platelet function disorders; patients on anticoagulation with low molecular weight heparin are allowedXx_NEWLINE_xXEvidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permittedXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant are ineligibleXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatient has a coagulopathy or bleeding disorderXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatients must not have a known bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXContraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agentsXx_NEWLINE_xXNo significant bleeding within the past 6 months; no bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).Xx_NEWLINE_xXEvidence of bleeding diathesisXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy.Xx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatients are excluded if they have evidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXKnown coagulopathy or bleeding disorders are controlledXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXKnown bleeding disorder or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXHistory or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleedingXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathy.Xx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy within the past 6 monthsXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy within 3 monthsXx_NEWLINE_xXPatients with a history of hemoptysis, bleeding diathesis, known platelet disorder, or coagulopathy are not eligibleXx_NEWLINE_xXKnown, existing uncontrolled coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or clinically significant coagulopathyXx_NEWLINE_xXEvidence of prior or current coagulopathy or bleeding diathesisXx_NEWLINE_xXClinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physicianXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of history of bleeding diathesis.Xx_NEWLINE_xXPatients must have no evidence of bleeding diathesis or coagulopathy; patients must have no pathologic condition other than mesothelioma that carries a high risk of bleedingXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXPre-existing bleeding diathesis, coagulopathy or hemorrhageXx_NEWLINE_xXParticipants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permittedXx_NEWLINE_xXThe subject has inherited bleeding diathesis or coagulopathy with the risk of bleedingXx_NEWLINE_xXPatients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.Xx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or clinically significant coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or a clinically significant coagulopathyXx_NEWLINE_xXPatients with an active, bleeding diathesis or significant coagulopathyXx_NEWLINE_xXPatients with evidence of a bleeding diathesisXx_NEWLINE_xXHistory of bleeding diathesis or coagulopathy. (Patients on stable anticoagulant therapy are eligible.)Xx_NEWLINE_xXPatient has a coagulopathy or bleeding disorder which is uncontrolled.Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathyXx_NEWLINE_xXPatients with uncontrolled coagulopathy or bleeding disorderXx_NEWLINE_xXEvidence or history of bleeding diathesis or uncontrolled coagulopathyXx_NEWLINE_xXEvidence or history of a bleeding diathesis or coagulopathy, including therapy-induced coagulopathyXx_NEWLINE_xXKnown, existing uncontrolled coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory of coagulopathy or known thrombophiliasXx_NEWLINE_xXConcurrent use of anti-coagulant drugs (not including prophylactic doses), history of coagulopathy, or evidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXPresence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).Xx_NEWLINE_xXNo known bleeding diathesis or coagulopathyXx_NEWLINE_xXKnown history of bleeding diathesis or coagulopathy (e.g., von Willebrand disease or hemophilia)Xx_NEWLINE_xXKnown, existing uncontrolled coagulopathyXx_NEWLINE_xXHistory of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXKnown, existing uncontrolled coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXNo history of clinical coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXCoagulopathy or bleeding diathesisXx_NEWLINE_xXNo known coagulopathyXx_NEWLINE_xXPatients must not have a known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the pastXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permittedXx_NEWLINE_xXPatients must not have any evidence of bleeding diathesisXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathy.Xx_NEWLINE_xXNonreversible or uncorrectable coagulopathy. INR should not be >1.5,Xx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of clinically significant bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation)Xx_NEWLINE_xXActive GI bleeding and any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agentsXx_NEWLINE_xXPatients with uncontrolled coagulopathy or bleeding disordersXx_NEWLINE_xXEvidence of bleeding diathesis or coagulopathy; patients that are on anticoagulation therapy for deep vein thrombosis (DVT) will be allowed to enroll and continue on the treatment dose of enoxaparin or other anticoagulation such a warfarinXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXKnown bleeding disorder or coagulopathyXx_NEWLINE_xXClinically significant coagulopathy or bleeding disorder.Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulationXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence of clinically significant bleeding diathesis or underlying coagulopathy (e.g. INR > 1.5 without vitamin K antagonist therapy), non-healing woundXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXPatients must not have a bleeding diathesis, hereditary of acquired bleeding disorder or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXHistory of bleeding diathesis or coagulopathy other than that due to anticoagulation therapyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathy at the time of enrollmentXx_NEWLINE_xXHistory or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleedingXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory of tumor-related or other serious hemorrhage, bleeding diathesis, or underlying coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXAny evidence of bleeding diathesis or coagulopathyXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXPre-existing coagulopathyXx_NEWLINE_xXClinically significant bleeding diathesis or coagulopathy, including known platelet function disordersXx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXUncorrected coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXKnown bleeding diathesis or coagulopathyXx_NEWLINE_xXSubjects with uncorrected coagulopathyXx_NEWLINE_xXUncorrectable coagulopathyXx_NEWLINE_xXCoagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)Xx_NEWLINE_xXEvidence or history of bleeding diathesis or coagulopathyXx_NEWLINE_xXPatient has an uncorrectable coagulopathyXx_NEWLINE_xXUncontrollable coagulopathyXx_NEWLINE_xXCoagulopathyXx_NEWLINE_xXUncontrolled coagulopathy or bleeding disordersXx_NEWLINE_xXKnown bleeding diathesis or coagulopathyXx_NEWLINE_xXHistory of coagulopathy or bleeding disordersXx_NEWLINE_xXCoagulopathyXx_NEWLINE_xXKnown inherited bleeding disorder or coagulopathyXx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) within 4 weeks of first study doseXx_NEWLINE_xXSevere coagulopathy or bleeding disorderXx_NEWLINE_xXUncorrectable coagulopathyXx_NEWLINE_xXUncorrectable coagulopathyXx_NEWLINE_xXKnown coagulopathyXx_NEWLINE_xXPatient must not have a known bleeding diathesis or coagulopathyXx_NEWLINE_xXCoagulopathyXx_NEWLINE_xXEvidence of a coagulopathyXx_NEWLINE_xX